|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 419.50 DKK | +3.00% |
|
-0.10% | -10.06% |
| Capitalization | 29.55B 4.59B 3.95B 3.68B 3.43B 6.38B 416B 6.86B 42.34B 16.7B 199B 17.2B 16.85B 725B | P/E ratio 2025 * |
4.95x | P/E ratio 2026 * | 33.6x |
|---|---|---|---|---|---|
| Enterprise value | 17.83B 2.77B 2.39B 2.22B 2.07B 3.85B 251B 4.14B 25.54B 10.07B 120B 10.38B 10.16B 437B | EV / Sales 2025 * |
2x | EV / Sales 2026 * | 3.99x |
| Free-Float |
99.18% | Yield 2025 * |
-
| Yield 2026 * | - |
Last Transcript: Zealand Pharma A/S
| 1 day | +3.00% | ||
| 1 week | -0.10% | ||
| Current month | -10.06% | ||
| 1 month | -9.20% | ||
| 3 months | -7.21% | ||
| 6 months | +16.79% | ||
| Current year | -10.06% |
| 1 week | 404 |  | 425.3 |
| 1 month | 390.5 | | 497.3 |
| Current year | 390.5 | | 478.5 |
| 1 year | 306.1 | | 808 |
| 3 years | 203 | | 972 |
| 5 years | 69.55 | | 972 |
| 10 years | 69.55 | | 972 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 52 | 2022-03-29 | |
| Director of Finance/CFO | - | 2022-10-31 | |
David M. Kendall
CTO | Chief Tech/Sci/R&D Officer | 64 | 2022-06-01 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 71 | - | |
Kirsten Drejer
BRD | Director/Board Member | 69 | 2018-04-18 |
| Director/Board Member | 67 | 2019-04-03 |
| Name | Varia. Jan 1. | Weight | AuM | |
|---|---|---|---|---|
 | +3.53% | 0% | 51 M€ |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +3.00% | -0.10% | -41.21% | +87.78% | 4.59B | |
| -0.49% | 0.00% | +8.75% | +88.27% | 49.24B | |
| +0.71% | +5.27% | +96.79% | +9.03% | 44.64B | |
| +1.35% | -8.27% | +122.62% | +744.25% | 34.43B | |
| +2.76% | +9.16% | -2.62% | -23.88% | 27.35B | |
| -0.60% | +7.34% | +121.49% | -42.68% | 21.08B | |
| +0.97% | +0.14% | +44.75% | -20.98% | 20.89B | |
| -0.74% | -5.17% | +104.56% | +168.59% | 14.29B | |
| +0.72% | -0.55% | +191.39% | - | 14.17B | |
| -1.33% | -13.41% | -10.46% | +271.24% | 13.14B | |
| Average | +0.64% | -0.52% | +63.61% | +142.40% | 24.38B | |
| Weighted average by Cap. | +0.55% | +0.49% | +66.76% | +151.35% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 8.92B 1.38B 1.19B 1.11B 1.03B 1.93B 126B 2.07B 12.79B 5.04B 59.94B 5.19B 5.09B 219B | 4.44B 689M 594M 553M 515M 959M 62.53B 1.03B 6.36B 2.51B 29.83B 2.58B 2.53B 109B |
| Net income | 5.98B 928M 800M 745M 693M 1.29B 84.18B 1.39B 8.56B 3.38B 40.15B 3.48B 3.41B 147B | 951M 148M 127M 119M 110M 205M 13.4B 221M 1.36B 538M 6.39B 554M 542M 23.34B |
| Net Debt | -11.72B -1.82B -1.57B -1.46B -1.36B -2.53B -165B -2.72B -16.8B -6.62B -78.76B -6.82B -6.68B -288B | -11.84B -1.84B -1.58B -1.48B -1.37B -2.56B -167B -2.75B -16.97B -6.69B -79.56B -6.89B -6.75B -291B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-01-16 | 419.50 kr | +3.00% | 266,027 |
| 26-01-15 | 407.30 kr | -1.50% | 263,489 |
| 26-01-14 | 413.50 kr | +0.85% | 301,560 |
| 26-01-13 | 410.00 kr | -0.12% | 240,218 |
| 26-01-12 | 410.50 kr | -2.24% | 280,780 |
Delayed Quote Nasdaq Copenhagen, January 16, 2026 at 11:20 am
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- ZEAL Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition